Kabra Drugs Ltd

Kabra Drugs Annual Report

Aanjaay Industries Ltd has submitted its Annual Report for FY 2025-2026 and issued notice for its 37th AGM scheduled for 30th September 2026.

Kabra Drugs Annual General Meeting

Aanjaay Industries Limited announced book closure dates from September 24th to September 30th, 2026, for its Annual General Meeting scheduled for September 30th, 2026.

Kabra Drugs Board Meeting Outcome

Aanjaay Industries Limited announced the notice for its 37th Annual General Meeting and approved board agenda items, including the appointment of directors and auditors.

Kabra Drugs Other Announcement

Aanjaay Industries Limited has shifted its registered office from Indore, Madhya Pradesh, to Chennai, Tamil Nadu, effective August 28, 2026.

Kabra Drugs Board Meeting Date

Aanjaay Industries Limited has scheduled a board meeting for September 2, 2026. The agenda includes approving the Director's Report and fixing details for the upcoming AGM.

Kabra Drugs Other Announcement

Aanjaay Industries Limited has filed its updated Board and Committee composition list in compliance with SEBI (LODR) regulations.

Kabra Drugs Management Change

Director Ms. Anand Anitha has resigned from the Board of Aanjaay Industries Limited, effective August 12, 2026, citing personal reasons.

Kabra Drugs Q1 FY27 Results: Turns Profitable, Net Profit ₹2.1 Cr

Kabra Drugs Ltd reported revenue from operations of ₹46.2 Cr (+541.7% YoY) and net profit of ₹2.1 Cr for Q1 FY27.

Key figure

Net profit ₹2.1 Cr

Kabra Drugs Board Meeting Date

Aanjaay Industries Limited will hold a Board Meeting on 12th August 2026. The meeting will consider the unaudited financial results and a Director's resignation.

Kabra Drugs Other Announcement

Kabra Drugs Ltd has filed its quarterly shareholding pattern for the quarter ended June 30, 2026, in compliance with SEBI regulatory requirements.

Kabra Drugs Other Announcement

Kabra Drugs Ltd has changed its name to Aanjaay Industries Limited effective July 6, 2026. The fresh Certificate of Incorporation has been filed with BSE.

Kabra Drugs Capacity Expansion: ₹200 Cr Investment

Kabra Drugs plans a ₹200 Crore pharmaceutical plant in Chhattisgarh. This expansion aims to boost manufacturing capacity and long-term growth.

Value

₹200.0 Cr

Kabra Drugs Annual General Meeting

Kabra Drugs Ltd shareholders approved a name change and alteration of the MOA object clause via postal ballot. Both resolutions passed with 99.85% votes in favor.

Kabra Drugs Results Update

Kabra Drugs Limited reported a turnaround FY26 with ₹93.23 Crore Total Income and positive PAT. The company is expanding into pharmaceutical manufacturing and AI-led defense technologies.

Value

₹93.23 Cr

Kabra Drugs Q4 FY26 Results: Net Profit ₹1.1 Cr, Up 175.0% YoY

Kabra Drugs Ltd reported revenue from operations of ₹35.4 Cr and net profit of ₹1.1 Cr (+175.0% YoY) for Q4 FY26.

Key figure

Net profit ₹1.1 Cr · +175.0% YoY

Kabra Drugs Financial Results

Kabra Drugs reported a total income of ₹93.23 Crore and a net profit of ₹4.96 Crore for FY2026. The Board approved these audited results today.

Value

₹93.23 Cr

Kabra Drugs Board Meeting Date

Kabra Drugs scheduled a board meeting for May 29, 2026, to approve quarterly financial results. The trading window remains closed for designated persons until result announcement.

Kabra Drugs Legal & Regulatory

Kabra Drugs received a waiver for ₹0.76 Crore in BSE penalties regarding board composition non-compliance. The exchange accepted the company's waiver application.

Value

₹0.76 Cr

Kabra Drugs Annual General Meeting

Kabra Drugs Limited published its Postal Ballot Notice in English and Hindi newspapers. This follows the completion of electronic dispatch to shareholders on May 12, 2026.

Kabra Drugs Annual General Meeting

Kabra Drugs Limited issued a postal ballot notice to shareholders for proposed business resolutions. Voting commences on May 12, 2026, and concludes on June 10, 2026.

Kabra Drugs Capacity Expansion

Kabra Drugs Limited announced strategic expansion into pharmaceutical manufacturing and AI-integrated defense technologies. Key initiatives include establishing an R&D facility at Cactus TECCI Park, Chennai, and obtaining a SCOMET license. The company also appointed Mr. Alagiamanavalan as an Independent Consultant for defense projects to drive diversification and long-term value creation.

Execution

Phase 1 focusing on South India; project implementation initiated immediately

Kabra Drugs Board Meeting Outcome

Kabra Drugs Limited approved expansion into generic branded formulations and entry into AI-driven defence manufacturing. The company will establish a dedicated AI & Defence R&D facility in Chennai and initiate SCOMET licensing. Additionally, the Board revised the postal ballot schedule, with e-voting set for May 12 to June 10, 2026.

Kabra Drugs Board Meeting Date

Kabra Drugs Limited has scheduled a Board Meeting on May 06, 2026. The board will consider pharmaceutical manufacturing expansion through strategic partners and evaluate defense manufacturing opportunities using Artificial Intelligence technologies. The meeting will be held at the company's Chennai corporate office.

Kabra Drugs Management Change

Kabra Drugs Limited appointed Ms. Monam Kapoor as an Additional Non-Executive Independent Director for a five-year term starting April 21, 2026. Ms. Kapoor is a BCA graduate with professional experience at Techtone (HK) Energy Company. The appointment is subject to shareholder approval and follows recommendations from the Nomination and Remuneration Committee.

Execution

5 years

Kabra Drugs Board Meeting Outcome

Kabra Drugs Limited approved the appointment of Ms. Monam Kapoor as an Independent Director for five years. The Board also approved significant business diversification into drones, AI, healthcare, and dairy sectors. A postal ballot will be conducted for a company name change and MOA alteration to reflect these new business objectives.

Kabra Drugs Capital Structure Change

Kabra Drugs Limited's board will meet on April 21, 2026, to approve diversifying into sectors including defense equipment, AI, and dairy. The board will also consider appointing Ms. Monam Kapoor as an Independent Director and initiate a postal ballot process for these proposals.

Kabra Drugs Other Announcement

Kabra Drugs Limited has submitted its quarterly compliance certificate for the period ended March 31, 2026, as per SEBI regulations. The Registrar and Share Transfer Agent, Skyline Financial Services, confirmed that physical share certificates received for dematerialization were duly verified, mutilated, and cancelled within 15 days.

Kabra Drugs Q3 FY26 Results: Turns Profitable, Net Profit ₹2.6 Cr

Kabra Drugs Ltd reported net profit of ₹2.6 Cr for Q3 FY26.

Key figure

Net profit ₹2.6 Cr